Cas:166978-46-7 7-BroMo-4,4-diMethyl-1-tetralone manufacturer & supplier

Chemical Name:7-BroMo-4,4-diMethyl-1-tetralone

CAS.NO:166978-46-7

Synonyms:7-bromo-4,4-dimethyl-2,3-dihydronaphthalen-1-one

Molecular Formula:C₁₂H₁₃BrO

Molecular Weight:253.13500

HS Code:2914700090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:325.6ºC at 760mmHg

Density:1.351g/cm3

Index of Refraction:1.556

PSA:17.07000

Exact Mass:252.01500

LogP:3.70320

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 7-bromo-4,4-dimethyl-2,3-dihydronaphthalen-1-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-bromo-4,4-dimethyl-2,3-dihydronaphthalen-1-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-bromo-4,4-dimethyl-2,3-dihydronaphthalen-1-one Use and application,7-bromo-4,4-dimethyl-2,3-dihydronaphthalen-1-one technical grade,usp/ep/jp grade.

Related News: Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as bulk pharmaceutical chemicals (BPCs). 7-BroMo-4,4-diMethyl-1-tetralone manufacturer The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 7-BroMo-4,4-diMethyl-1-tetralone supplier Active pharmaceutical ingredients affect the structure and function of the human body. Inactive ingredients in a pharmaceutical may be referred to as bulk pharmaceutical chemicals (BPCs). 7-BroMo-4,4-diMethyl-1-tetralone vendor On the basis of achieving low-cost and high-quality processes, production capacity will become the core driving force for API companies to break through sales bottlenecks. 7-BroMo-4,4-diMethyl-1-tetralone factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.